{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:14:58Z","timestamp":1778710498857,"version":"3.51.4"},"reference-count":46,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Daiichi Sankyo India Pharma Private Limited"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,12]]},"abstract":"ABSTRACT<\/jats:title>\n \n RBx 11760, a bi-aryl oxazolidinone, was investigated for antibacterial activity against Gram-positive bacteria. The MIC\n 90<\/jats:sub>\n s of RBx 11760 and linezolid against\n Staphylococcus aureus<\/jats:named-content>\n were 2 and 4 mg\/liter, against\n Staphylococcus epidermidis<\/jats:named-content>\n were 0.5 and 2 mg\/liter, and against\n Enterococcus<\/jats:named-content>\n were 1 and 4 mg\/liter, respectively. Similarly, against\n Streptococcus pneumoniae<\/jats:named-content>\n the MIC\n 90<\/jats:sub>\n s of RBx 11760 and linezolid were 0.5 and 2 mg\/liter, respectively. In time-kill studies, RBx 11760, tedizolid, and linezolid exhibited bacteriostatic effect against all tested strains except\n S. pneumoniae<\/jats:named-content>\n . RBx 11760 showed 2-log\n 10<\/jats:sub>\n kill at 4\u00d7 MIC while tedizolid and linezolid showed 2-log\n 10<\/jats:sub>\n and 1.4-log\n 10<\/jats:sub>\n kill at 16\u00d7 MIC, respectively, against methicillin-resistant\n S. aureus<\/jats:named-content>\n (MRSA) H-29. Against\n S. pneumoniae<\/jats:named-content>\n 5051, RBx 11760 showed bactericidal activity, with 4.6-log\n 10<\/jats:sub>\n kill at 4\u00d7 MIC compared to 2.42-log\n 10<\/jats:sub>\n and 1.95-log\n 10<\/jats:sub>\n kill for tedizolid and linezolid, respectively, at 16\u00d7 MIC. RBx 11760 showed postantibiotic effects (PAE) at 3 h at 4 mg\/liter against MRSA H-29, and linezolid showed the same effect at 16 mg\/liter. RBx 11760 inhibited biofilm production against methicillin-resistant\n S. epidermidis<\/jats:named-content>\n (MRSE) ATCC 35984 in a concentration-dependent manner. In a foreign-body model, linezolid and rifampin resulted in no advantage over stasis, while the same dose of RBx 11760 demonstrated a significant killing compared to the initial control against\n S. aureus<\/jats:named-content>\n (\n P<\/jats:italic>\n < 0.05) and MRSE (\n P<\/jats:italic>\n < 0.01). The difference in killing was statistically significant for the lower dose of RBx 11760 (\n P<\/jats:italic>\n < 0.05) versus the higher dose of linezolid (\n P<\/jats:italic>\n > 0.05 [not significant]) in a groin abscess model. In neutropenic mouse thigh infection, RBx 11760 showed stasis at 20 mg\/kg of body weight, whereas tedizolid showed the same effect at 40 mg\/kg. These data support RBx 11760 as a promising investigational candidate.\n <\/jats:p>","DOI":"10.1128\/aac.00453-16","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T01:59:47Z","timestamp":1474336787000},"page":"7134-7145","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":23,"title":["In Vitro<\/i>\n and\n In Vivo<\/i>\n Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria"],"prefix":"10.1128","volume":"60","author":[{"given":"Tarani Kanta","family":"Barman","sequence":"first","affiliation":[{"name":"Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India"},{"name":"Centre for Biomedical Engineering, Indian Institute of Technology, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarun","family":"Mathur","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tridib","family":"Chaira","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics & Metabolism, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ramkumar","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vandana","family":"Kalia","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India"},{"name":"Department of Scientific and Industrial Research, Government of India, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhvi","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Pandya","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay Singh","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biswajit","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilip J.","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Hamidullah","sequence":"additional","affiliation":[{"name":"Central Drug Research Institute (CDRI), Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rituraj","family":"Konwar","sequence":"additional","affiliation":[{"name":"Central Drug Research Institute (CDRI), Lucknow, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. Samuel","family":"Raj","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India"},{"name":"Centre for Drug Design Discovery and Development (C4D), SRM University Haryana, Sonepat, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harpal","family":"Singh","sequence":"additional","affiliation":[{"name":"Centre for Biomedical Engineering, Indian Institute of Technology, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/2047-2994-3-18"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767160-00005"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01592.x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq067"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1270-6"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0909.020383"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg457"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.03.012"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0702.010226"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.5.6.961"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm258"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00616-09"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/502357"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00185-10"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg104"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks354"},{"key":"e_1_3_3_18_2","volume-title":"Zyvox (linezolid package insert) prescribing information","author":"Pharmacia & Upjohn Co","year":"2015","unstructured":"Pharmacia & Upjohn Co. 2015. Zyvox (linezolid package insert) prescribing information. New York, Pharmacia & Upjohn Co., New York, NY."},{"key":"e_1_3_3_19_2","first-page":"555","article-title":"Tedizolid phosphate (Sivextro): a second generation oxazolidinone to treat acute bacterial skin and skin structure infections","volume":"39","author":"Wong E","year":"2014","unstructured":"Wong E, Rab S. 2014. Tedizolid phosphate (Sivextro): a second generation oxazolidinone to treat acute bacterial skin and skin structure infections. P T 39:555\u2013579.","journal-title":"P T"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00502-11"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.08.025"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr033"},{"key":"e_1_3_3_23_2","volume-title":"Approved standard M7-A09","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A09. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_24_2","volume-title":"Antibiotics in laboratory medicine","author":"Lorian V","year":"2005","unstructured":"Lorian V. 2005. Antibiotics in laboratory medicine, 5th ed. Lippincott Williams and Wilkins, Philadelphia, PA.","edition":"5"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1148-1150.2003"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.04.012"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00887-08"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.2.882-890.2003"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.5.2627-2632.1999"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/38.4.641"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3484-3489.2002"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm800379d"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1517\/17460440903493449"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70316-4"},{"key":"e_1_3_3_35_2","first-page":"390","article-title":"Some new concepts in antibacterial drug therapy","volume":"34","author":"Sharma KK","year":"2002","unstructured":"Sharma KK, Sangraula H, Mediratta PK. 2002. Some new concepts in antibacterial drug therapy. Ind J Pharmacol 34:390\u2013396.","journal-title":"Ind J Pharmacol"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_D.149"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2007.06.004"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.10.010"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.37.1.318-326.1982"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1318"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01565-10"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00871-09"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342150-00007"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2005.130783"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.12.3789-3794.2003"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00358-7"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00453-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00453-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:29:28Z","timestamp":1645475368000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00453-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1128\/AAC.00453-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.00453-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"2016-02-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}